Skip to content
TrialScanner

NCT04379518

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Phase 1/Phase 2TerminatedAIMCollaborator

Registry record

Lead sponsor
Roswell Park Cancer Institute
Conditions
Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Symptomatic COVID-19 Infection Laboratory-Confirmed
Primary completion
Mar 15, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04379518 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04379518: Rintatolimod and IFN... | TrialScanner